World AMR Awareness Week 2026 (November 18–24): Working together to combat antimicrobial resistance

How the DZIF is addressing the spread of drug-resistant bacteria

© WHO

The emergence and spread of antimicrobial resistance (AMR) threaten the treatment of infectious diseases worldwide. When antibiotics no longer work, bacterial infections become increasingly difficult to treat. World AMR Awareness Week (WAAW) 2026 is held under the theme “One Health, one action: Prevent AMR now” and calls for joint efforts to curb the emergence and spread of resistance. The German Center for Infection Research (DZIF) is pursuing a broad range of research approaches to address this challenge—from the early detection of drug-resistant pathogens and the development of new antimicrobial agents to innovative treatment and prevention strategies.

The following examples showcase selected DZIF research projects and introduce the scientists working to develop solutions to this global challenge.

Detecting resistance and preventing its spread

GUARDIAN research project: Detecting and containing antimicrobial resistance at an early stage

Funded by the German Federal Ministry of Research, Technology and Space (BMFTR) with €3.5 million, the GUARDIAN research project investigates the spread of antibiotic-resistant bacteria, particularly multidrug-resistant Enterobacterales. Using genomic analyses and artificial intelligence, the researchers aim to detect outbreaks at an early stage, trace transmission pathways, and develop prevention strategies. The project takes an interdisciplinary One Health approach that takes into account the health of humans, animals, and the environment.

Prof. Torsten Hain and Prof. Can Imirzalioglu (Justus Liebig University Giessen)

More information about the project

Rapid test for vancomycin-resistant enterococci

Vancomycin-resistant enterococci (VRE) are among the most problematic pathogens found in hospitals. One diagnostic challenge is that standard testing methods do not always reliably detect one of the two relevant mechanisms responsible for vancomycin resistance. DZIF researchers are therefore working with the company Coris BioConcept to develop an antibody-based rapid test that can reliably detect both relevant resistance mechanisms and improve diagnostics.

Dr. Alexander Klimka (University of Cologne)

More information about the project

Developing new antimicrobial agents against resistant pathogens

BTZ-043: A new drug candidate against multidrug-resistant tuberculosis

The antibiotic BTZ-043, developed by DZIF researchers in collaboration with the UNITE4TB consortium, offers new prospects for treating multidrug-resistant tuberculosis. Studies show that the drug penetrates deep into tuberculosis-associated tissue lesions, where it accumulates. This allows it to reach tuberculosis bacteria in hard-to-access areas. BTZ-043 is currently being investigated in a Phase II clinical trial.

Prof. Dr. Andreas Römpp (University of Bayreuth) and Dr. Kerstin Walter (Research Center Borstel, Leibniz Lung Center)

More on the latest research findings, the BTZ-043 project, and UNITE4TB

Corramycin: A novel mechanism of action against tuberculosis

Tuberculosis treatment is lengthy and becomes even more challenging when the bacteria are drug-resistant. The natural product corramycin offers a new approach: It targets the tuberculosis pathogen Mycobacterium tuberculosis through a previously unknown mechanism of action. This could make it a starting point for the development of new tuberculosis drugs.

Prof. Dr. Dr. Jan Rybniker (University Hospital Cologne)

More information about the project

Argyrin B: A natural product that selectively targets Clostridioides difficile

Broad-spectrum antibiotics can also damage the beneficial gut microbiome. The natural product argyrin B could offer a more targeted alternative: Studies have shown that it acts against the pathogen Clostridioides difficile while largely sparing beneficial gut bacteria.

Prof. Dr. Rolf Müller (Helmholtz Institute for Pharmaceutical Research Saarland)

More information about the project

Corallopyronin A: A natural product targeting antibiotic-resistant pathogens

Corallopyronin A (CorA) is a natural product derived from soil bacteria that is manufactured using biotechnological processes. In addition to its development as a treatment for parasitic worm infections, the compound is also being investigated for use against antibiotic-resistant gonococci and methicillin-resistant Staphylococcus aureus (MRSA). Following a successful technology transfer, the company Phyton Biotech is now producing CorA in sufficient quantities and at Good Manufacturing Practice (GMP) quality for clinical trials. A development partnership has also been established with the Japanese company Eisai.

Dr. Andrea Schiefer, Dr. Kenneth Pfarr, Prof. Karl Wagner, and Prof. Achim Hörauf (University Hospital Bonn)

More information about the project

Alternative therapy and prevention strategies

PANTIPA: Antibody therapy against Pseudomonas aeruginosa

The DZIF flagship project PANTIPA is developing an antibody-based therapy against the difficult-to-treat pathogen Pseudomonas aeruginosa. The monoclonal antibody is designed to specifically block a disease-causing factor produced by the bacterium without killing the pathogen itself. Following successful preclinical studies, process development and GMP-compliant manufacturing of the drug candidate are now getting underway in collaboration with the Celonic Group, paving the way for clinical testing.

Prof. Dr. Dr. Jan Rybniker and PD Dr. Dr. Alexander Simonis (University Hospital of Cologne)

More information about the project

Phage therapy: Establishing common standards for clinical use

Bacteriophages can offer a treatment option for difficult-to-treat bacterial infections, particularly when antibiotics are no longer effective. Until now, however, there have been no uniform standards for their clinical use. An international guideline developed with the participation of DZIF researchers establishes, for the first time, a common framework for the quality, production, and use of personalized phage therapies. It is intended to support their safe application in clinical practice.

Dr. Annika Claßen and Prof. Dr. Maria J.G.T. Vehreschild (University Hospital Cologne) as well as PD Dr. Silvia Würstle and Dr. Simone Lieberknecht-Jouy (Johann Wolfgang Goethe University Frankfurt am Main)

Further information on the guideline and the PhageNet DZIF network

PhageLive: Targeted removal of multidrug-resistant bacteria from the gut

In particularly vulnerable patients, such as those undergoing cancer treatment, colonization with multidrug-resistant gut bacteria can lead to severe infections. The DZIF project PhageLive is developing a targeted approach to remove these pathogens from the gut by combining bacteriophages, which kill specific bacteria, with beneficial gut bacteria. This combination is intended to preserve the natural gut microbiota as much as possible, sustainably reduce the number of resistant bacteria, and lower the risk of infection. The goal is to lay the groundwork for developing a new therapeutic product.

Dr. Annika Claßen (University Hospital Cologne), Prof. Till Strowig und Dr. Lisa Osbelt-Block (Helmholtz Center for Infection Research)

More information about the project

PROTON: A novel drug approach targeting Staphylococcus aureus

The PROTON research project is investigating a novel drug approach against the pathogen Staphylococcus aureus. The so-called pathoblocker does not target bacterial growth but instead acts against a toxin involved in damaging lung tissue and immune cells. By specifically inhibiting this disease-causing mechanism, the approach could carry a lower risk of resistance development than conventional antibiotics. The Falling Walls Foundation has nominated PROTON as a “Science Breakthrough of the Year 2026” in the Life Sciences category.

Prof. Dr. Mark Brönstrup (Helmholtz Centre for Infection Research)

More information about the project

Harnessing the gut microbiome to prevent infections

A healthy gut microbiome can help protect against infections. Researchers have discovered that certain bacteria belonging to the species Klebsiella oxytoca can displace disease-causing pathogens in the gut. Based on this finding, they aim to develop a live biotherapeutic product to prevent serious infections. The DZIF is providing €2.2 million in funding to advance product development through to the first clinical trial in humans.

Dr. Lisa Osbelt-Block and Prof. Dr. Till Strowig (Helmholtz Centre for Infection Research)

More information about the project

Research Collaborations and Networks: Working Together Against AMR

Developing new treatments for antimicrobial resistance requires collaboration among the scientific community, industry, and policymakers. The DZIF is therefore actively involved in several national and international networks. As a founding member of INCATE, it supports the development of new antibacterial therapies. Through the German Network against Antimicrobial Resistance (DNAMR), it works alongside other stakeholders to promote the development of new antibiotics. The Parliamentary Group on Antimicrobial Resistance (PKAMR), which includes representatives of the DNAMR, also fosters dialogue between policymakers and scientists and helps put AMR on the political agenda.

Dr. Timo Jäger (DZIF Managing Director and DZIF representative in the DNAMR)

Further information: DNAMR | INCATE | Parliamentary Group Against Antimicrobial Resistance

For interview requests, please contact the researchers listed above directly and copy the DZIF Press Office (presse@dzif.de). Please credit the DZIF as the source in interviews and publications, including online content.

Sign in for the DZIF-Press mailing list now

Receive the DZIF press releases directly into your inbox.